Fate Therapeutics, Inc. is betting big on programmed cell therapies. The company is building a pipeline that targets both cancer and tough immune disorders. Its main focus: chimeric antigen receptor (CAR) engineered natural killer (NK) and T-cell therapies. These are designed as off-the-shelf options for patients who have few choices right now.
FT836 stands out among the company’s candidates. It is in preclinical development for several tumor types. FT522 is being developed for B-cell lymphoma and autoimmunity. Fate’s CAR T-cell programs go beyond cancer. FT819 is moving forward for systemic lupus erythematosus. FT839 is aimed at complex autoimmune diseases. FT825 is designed for solid tumors. This range shows Fate’s strategy. The company is targeting both blood cancers and solid tumors, plus autoimmune diseases that standard treatments struggle to control.
In September 2026, Fate Therapeutics received a $15 million grant from the California Institute for Regenerative Medicine to support its Phase 2 RECLAIM-LN trial of FT819 in lupus nephritis.
Pipeline built on iPSC-derived cell platforms
Fate Therapeutics uses induced pluripotent stem cell (iPSC) technology to make standardized, programmable cell therapies. This method aims to solve the problems of autologous cell therapies, which can be unpredictable and hard to scale. The company wants to offer products that are ready to use and easy to produce. Fate has a collaboration and option deal with Ono Pharmaceutical Co. Ltd. They are working together to develop and commercialize iPSC-derived CAR T-cell candidates for solid tumors. This shows that the industry is looking to expand cell therapy beyond blood cancers.
Most of Fate’s candidates are still in preclinical or early clinical stages. But the company’s focus on both cancer and autoimmunity sets it apart from many other cell therapy developers. The pipeline is broad. This matches recent research efforts to expand CAR-based therapies, as seen in reported earlier attempts to make solid tumors more open to immune attack.
FT819 is described by Fate as an off-the-shelf CD19-targeting CAR T-cell product candidate. It has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. It is also part of the FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot program. An official SEC regulatory filing shows that the Phase 2 RECLAIM-LN study will enroll about 53 patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) and class III/IV lupus nephritis. The main goal is complete kidney response at week 26.
In late September 2026, Fate said FT839 is moving into clinical development for autoimmune diseases. The company plans a basket study to start enrolling in the second half of 2026. Market reports say FT839 will be tested with or without conditioning chemotherapy. Fate wants to try several treatment strategies for hard-to-treat autoimmune diseases.
Fate Therapeutics continues to position itself as a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, confirming in 2026 public statements the presence of iPSC-derived T-cell and NK-cell product candidates with novel synthetic controls of cell function.
Strategic positioning in a competitive landscape
Fate Therapeutics was founded in 2007. Its headquarters are in San Diego, California. The company is working at the crossroads of oncology and immunology. Its focus on iPSC-derived, off-the-shelf cell therapies could help solve manufacturing and access problems that have slowed the spread of CAR T-cell treatments. Most of Fate’s programs are still preclinical. The real impact in the clinic and market is not clear yet.
The pipeline shows a clear bet on cell engineering and disease biology coming together. Fate is targeting cancer and autoimmune disorders with programmable cell therapies. The company is moving into some of medicine’s toughest areas. If its iPSC-derived candidates work as planned, Fate could help change what cell therapy can do. But the road from lab to clinic is never simple in this field.
